生物活性 | |||
---|---|---|---|
描述 | Bevacizumab is a recombinant humanized monoclonal immunoglobulin (Ig) G1 antibody that binds to all isoforms and bioactive proteolytic fragments of human vascular endothelial growth factor-A (VEGF), which is essential for both normal and tumor angiogenesis. It is approved for the treatment of patients with metastatic colorectal cancer, advanced nonsquamous non-small cell lung cancer, metastatic renal cell carcinoma, recurrent glioblastoma, advanced cervical cancer, and platinum-resistant ovarian cancer. Product Name: Bevacizumab Reactivities: Human Target: VEGF Recommended Dilution Buffer: PBS, pH 7.4. Contains no stabilizers or preservatives. Concentration: 25.2mg/mL Storage: 2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage. |